Genentech Cancer Antibody, Son of Rituxan, Nails Pivotal Study – Xconomy
|
Genentech Cancer Antibody, Son of Rituxan, Nails Pivotal Study
Xconomy Genentech has been searching for years to find a way to improve upon rituximab (Rituxan), which set a gold standard 15 years ago as part of the first generation of targeted antibody cancer drugs. Now it looks like Genentech has finally nailed a new and … Roche Experimental Leukemia Drug Helps Shrink TumorsBloomberg Genentech’s Obinutuzumab (GA101) Significantly Reduced the Risk of Disease …Wall Street Journal (press release) |





